RxDoctor Payments DataLook up a doctor →

James Barker, MD

Psychiatry · Hickory, NCNPI 1922189927

Payments from drug & device makers

$4,085,945in general payments, 2019–2025

Across 3,559 payments — averaging $1148.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.1M
  • Alkermes, Inc.$662K
  • Johnson & Johnson$532K
  • Sumitomo Pharma America, Inc.$400K
  • Axsome Therapeutics, Inc.$320K
  • E.r. Squibb & Sons, L.L.C.$306K
  • plus $764K from 34 others

What the payments were for

  • Consulting fees$191,5049%
  • Speaking & faculty fees$1,746,76382%
  • Travel & lodging$141,5317%
  • Food & beverage$61,3263%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,085,945 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$131,295
Medicare patients
108
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate46$412,977
SpravatoEsketamine Hcl240$272,149
CaplytaLumateperone Tosylate112$213,795
AristadaAripiprazole Lauroxil32$106,045
Invega SustennaPaliperidone Palmitate20$72,077
TrintellixVortioxetine Hydrobromide54$35,600
LybalviOlanzapine/Samidorphan Malate15$22,258
OzempicSemaglutide20$21,881
ViibrydVilazodone Hcl12$6,720
Clozapine63$6,375
Bupropion XlBupropion Hcl195$6,317
Lisdexamfetamine Dimesylate13$4,545
Gabapentin125$3,809
Lamotrigine176$2,953
Quetiapine Fumarate106$2,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$241,830$412,97746 claims
Johnson & JohnsonSpravato, Invega Sustenna$531,620$344,226260 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$45,625$213,795112 claims
Alkermes, Inc.Aristada, Lybalvi$661,862$128,30447 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$907$35,60054 claims
Novo NordiskOzempic$104$21,88120 claims
AbbVieViibryd$295,573$6,72012 claims
Lilly USA, LLCOlanzapine$20$1,58958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →